vs
LESAKA TECHNOLOGIES INC（LSAK）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
LESAKA TECHNOLOGIES INC的季度营收约是再鼎医药的23.6倍（$3.0B vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.2%），过去两年LESAKA TECHNOLOGIES INC的营收复合增速更高（341.6% vs 20.8%）
莱萨卡科技是一家总部位于南非的金融科技公司，目前同时在纳斯达克交易所与约翰内斯堡证券交易所挂牌上市。公司核心业务聚焦于金融普惠，面向此前金融服务覆盖不足的社区与商户提供各类金融服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
LSAK vs ZLAB — 直观对比
营收规模更大
LSAK
是对方的23.6倍
$127.1M
营收增速更快
ZLAB
高出16.9%
0.2%
两年增速更快
LSAK
近两年复合增速
20.8%
损益表 — Q1 FY2027 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.0B | $127.1M |
| 净利润 | $437.0K | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 2.2% | -54.6% |
| 净利率 | 0.0% | — |
| 营收同比 | 0.2% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LSAKZLAB
| Q3 26 | $3.0B | — | ||
| Q2 26 | $3.1B | — | ||
| Q4 25 | $178.7M | $127.1M | ||
| Q3 25 | $171.4M | $115.4M | ||
| Q2 25 | $168.5M | $109.1M | ||
| Q1 25 | $161.4M | $105.7M | ||
| Q4 24 | $176.2M | $108.5M | ||
| Q3 24 | $153.6M | $101.8M |
净利润LSAKZLAB
| Q3 26 | $437.0K | — | ||
| Q2 26 | $3.6M | — | ||
| Q4 25 | $3.6M | — | ||
| Q3 25 | $-4.3M | $-36.0M | ||
| Q2 25 | $-28.4M | $-40.7M | ||
| Q1 25 | $-22.1M | $-48.4M | ||
| Q4 24 | $-32.5M | — | ||
| Q3 24 | $-4.5M | $-41.7M |
毛利率LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | 31.4% | 51.0% | ||
| Q3 25 | 30.9% | 59.5% | ||
| Q2 25 | 28.9% | 60.6% | ||
| Q1 25 | 27.5% | 63.6% | ||
| Q4 24 | 25.7% | 61.5% | ||
| Q3 24 | 22.6% | 64.1% |
营业利润率LSAKZLAB
| Q3 26 | 2.2% | — | ||
| Q2 26 | 1.2% | — | ||
| Q4 25 | 1.2% | -54.6% | ||
| Q3 25 | 0.2% | -42.3% | ||
| Q2 25 | -16.7% | -50.3% | ||
| Q1 25 | 0.4% | -53.3% | ||
| Q4 24 | 0.3% | -62.6% | ||
| Q3 24 | -0.0% | -66.6% |
净利率LSAKZLAB
| Q3 26 | 0.0% | — | ||
| Q2 26 | 0.1% | — | ||
| Q4 25 | 2.0% | — | ||
| Q3 25 | -2.5% | -31.2% | ||
| Q2 25 | -16.9% | -37.3% | ||
| Q1 25 | -13.7% | -45.8% | ||
| Q4 24 | -18.4% | — | ||
| Q3 24 | -3.0% | -40.9% |
每股收益（稀释后）LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | $0.04 | $-0.05 | ||
| Q3 25 | $-0.05 | $-0.03 | ||
| Q2 25 | $-0.40 | $-0.04 | ||
| Q1 25 | $-0.27 | $-0.04 | ||
| Q4 24 | $-0.40 | $-0.09 | ||
| Q3 24 | $-0.07 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $689.6M |
| 总债务越低越好 | $3.2B | — |
| 股东权益账面价值 | — | $715.5M |
| 总资产 | $11.5B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LSAKZLAB
| Q3 26 | $1.5B | — | ||
| Q2 26 | $1.2B | — | ||
| Q4 25 | $69.5M | $689.6M | ||
| Q3 25 | $72.2M | $717.2M | ||
| Q2 25 | $76.5M | $732.2M | ||
| Q1 25 | $71.0M | $757.3M | ||
| Q4 24 | $60.6M | $779.7M | ||
| Q3 24 | $49.7M | $616.1M |
总债务LSAKZLAB
| Q3 26 | $3.2B | — | ||
| Q2 26 | $3.4B | — | ||
| Q4 25 | $216.8M | — | ||
| Q3 25 | $208.1M | — | ||
| Q2 25 | $200.8M | — | ||
| Q1 25 | $194.7M | — | ||
| Q4 24 | $148.7M | — | ||
| Q3 24 | $148.5M | — |
股东权益LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | $180.6M | $715.5M | ||
| Q3 25 | $170.4M | $759.9M | ||
| Q2 25 | $161.6M | $791.7M | ||
| Q1 25 | $185.2M | $810.8M | ||
| Q4 24 | $193.3M | $840.9M | ||
| Q3 24 | $184.2M | $667.7M |
总资产LSAKZLAB
| Q3 26 | $11.5B | — | ||
| Q2 26 | $11.7B | — | ||
| Q4 25 | $704.6M | $1.2B | ||
| Q3 25 | $652.9M | $1.2B | ||
| Q2 25 | $653.7M | $1.2B | ||
| Q1 25 | $649.2M | $1.2B | ||
| Q4 24 | $640.6M | $1.2B | ||
| Q3 24 | $551.9M | $985.3M |
负债/权益比LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.81× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | $-10.9M | $-26.0M | ||
| Q3 25 | $8.9M | $-32.0M | ||
| Q2 25 | $-9.1M | $-31.0M | ||
| Q1 25 | $10.7M | $-61.7M | ||
| Q4 24 | $-9.2M | $-55.8M | ||
| Q3 24 | $-4.1M | $-26.8M |
自由现金流LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | $-14.8M | $-26.7M | ||
| Q3 25 | $4.9M | $-35.0M | ||
| Q2 25 | $-13.2M | $-33.9M | ||
| Q1 25 | $7.8M | $-63.2M | ||
| Q4 24 | $-15.5M | $-58.4M | ||
| Q3 24 | $-8.1M | $-28.2M |
自由现金流率LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | -8.3% | -21.0% | ||
| Q3 25 | 2.9% | -30.4% | ||
| Q2 25 | -7.8% | -31.1% | ||
| Q1 25 | 4.9% | -59.9% | ||
| Q4 24 | -8.8% | -53.8% | ||
| Q3 24 | -5.3% | -27.7% |
资本支出强度LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | 2.2% | 0.5% | ||
| Q3 25 | 2.3% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 1.7% | 1.5% | ||
| Q4 24 | 3.6% | 2.4% | ||
| Q3 24 | 2.6% | 1.3% |
现金转化率LSAKZLAB
| Q3 26 | — | — | ||
| Q2 26 | — | — | ||
| Q4 25 | -2.99× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LSAK
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
